Lumida
/AQST
⌘K
Aquestive Therapeutics Inc

Aquestive Therapeutics Inc

AQST
$5.02USD-2.71%-0.14 today

MARKET CAP

633.8M

P/E (TTM)

FWD P/E

DAY RANGE

$5 – $5

52W RANGE

$3
$8

AI Summary

Stalk
Buy NowMedium

Stage 2 advancing remains intact despite the late‐June exhaustion signal. Price has retraced into the rising 9/21/50 EMA confluence on neutral RSI and OB/OS context, offering a disciplined entry. Speculative intent favors buying this pullback while preserving the uptrend and monitoring for an EMA breach.

  • Positive Anaphylm PK/usability studies bolster FDA approval prospects.
  • Q2 revenue $13.82M (+18% YoY) with FY guidance of $46–50M.
  • Net loss $22.9M in Q2 highlights persistent cash burn.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$50.8M$47.7M$50.6M$57.6M$44.5M
YoY %+10.9%-6.2%+6.1%+13.8%-22.6%
P / Sales2.9x0.9x2.4x5.4x15.5x
EV / Sales5.2x4.0x5.2x6.9x17.1x
Gross Profit, Adj.$35.8M$28.3M$29.8M$39.7M$26.0M
YoY %+9.0%-21.1%+5.2%+33.4%-34.5%
Margin %70.5%59.3%58.8%69.0%58.3%
EV / Gross Profit7.4x6.8x8.8x10.0x29.4x
EBITDA, Adj.$-31.7M$-39.7M$-13.8M$-35.5M$-76.2M
YoY %+19.6%-25.1%+65.3%-158.1%-114.7%
Margin %-62.4%-83.2%-27.2%-61.7%-171.2%
EV / EBITDA-8.3x-4.8x-19.1x-11.2x-10.0x
EBIT$-34.7M$-42.1M$-15.1M$-36.2M$-76.8M
YoY %+19.1%-21.3%+64.1%-139.9%-111.9%
Margin %-68.2%-88.2%-29.9%-62.9%-172.4%
EV / EBIT-7.6x-4.6x-17.4x-11.0x-9.9x
Net Income$-70.5M$-54.4M$-7.9M$-44.1M$-83.8M
YoY %-26.5%+22.9%+85.5%-460.8%-89.8%
Net Margin-138.8%-114.1%-15.6%-76.7%-188.1%
EPS (GAAP)-$1.85-$1.12-$0.13-$0.51-$0.78
YoY %-11.4%+39.5%+88.4%-292.3%-52.9%